Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Gorilla and King Portfolio Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Apollo who wrote (49096)	11/25/2001 12:36:46 PM
From: hueyone	Respond to of 54805

I would have to say your view as an investor and my view as a sepsis researcher are widely disparate. Apollo: Thank you for adding an expert opinion to this subject. It is interesting that as an "insider" in this field, that you do not find any compelling investments. I propose this phenomenon is not limited to biotech. I would venture to guess that, although the risks in biotech are higher, it is for the similar reasons that upper level management in technology companies are not making purchases at market prices in their fields. While the generous availability of cheap stock options for upper managment has a lot to do with this, perhaps these managers privately held outlook regarding risk/reward profile for investment in these companies at current market prices is much less favorable than that held by many of us wide-eyed, optimistic, technology investors. Best, Huey